Please use a PC Browser to access Register-Tadawul
Ocular Therapeutix Showcases Progress on AXPAXLI for Wet AMD and Diabetic Retinopathy at JPM 2025
Ocular Therapeutix Inc OCUL | 7.28 | -2.67% |
Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress across its registrational program for AXPAXLI™ in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic retinopathy (NPDR), and the Company's strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2025).